Free Trial
NASDAQ:RCKT

Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis

Rocket Pharmaceuticals logo
$3.15 -0.06 (-1.87%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$3.18 +0.04 (+1.11%)
As of 10/3/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)

Advanced

Key Stats

Today's Range
$3.13
$3.27
50-Day Range
$2.86
$3.75
52-Week Range
$2.19
$18.89
Volume
2.63 million shs
Average Volume
2.18 million shs
Market Capitalization
$339.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67
Consensus Rating
Hold

Company Overview

Rocket Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
96th Percentile Overall Score

RCKT MarketRank™: 

Rocket Pharmaceuticals scored higher than 96% of companies evaluated by MarketBeat, and ranked 51st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Rocket Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 8 buy ratings, 8 hold ratings, and 2 sell ratings.

  • Upside Potential

    Rocket Pharmaceuticals has a consensus price target of $16.67, representing about 429.1% upside from its current price of $3.15.

  • Amount of Analyst Coverage

    Rocket Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Rocket Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.83) to ($2.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Rocket Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Rocket Pharmaceuticals is -1.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Rocket Pharmaceuticals has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Rocket Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.80% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rocket Pharmaceuticals has recently decreased by 3.87%, indicating that investor sentiment is improving.
  • Dividend Yield

    Rocket Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Rocket Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.80% of the outstanding shares of Rocket Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Rocket Pharmaceuticals has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Rocket Pharmaceuticals has recently decreased by 3.87%, indicating that investor sentiment is improving.
  • News Sentiment

    Rocket Pharmaceuticals has a news sentiment score of -0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Rocket Pharmaceuticals this week, compared to 22 articles on an average week.
  • Search Interest

    Only 16 people have searched for RCKT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Rocket Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Rocket Pharmaceuticals insiders have sold 214.25% more of their company's stock than they have bought. Specifically, they have bought $34,100.00 in company stock and sold $107,159.00 in company stock.

  • Percentage Held by Insiders

    24.76% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Rocket Pharmaceuticals' insider trading history.
Receive RCKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCKT Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
See More Headlines

RCKT Stock Analysis - Frequently Asked Questions

Rocket Pharmaceuticals' stock was trading at $12.57 at the beginning of the year. Since then, RCKT stock has decreased by 74.9% and is now trading at $3.15.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) announced its earnings results on Thursday, August, 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.02.

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rocket Pharmaceuticals investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Marinus Pharmaceuticals (MRNS), Waste Connections (WCN), Humana (HUM), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
8/07/2025
Today
10/05/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RCKT
CIK
1281895
Employees
240
Year Founded
2018

Price Target and Rating

High Price Target
$44.00
Low Price Target
$5.00
Potential Upside/Downside
+429.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.51)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$258.75 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-65.11%
Return on Assets
-55.99%

Debt

Debt-to-Equity Ratio
0.05
Current Ratio
6.39
Quick Ratio
6.39

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.08 per share
Price / Book
0.62

Miscellaneous

Outstanding Shares
107,900,000
Free Float
81,187,000
Market Cap
$339.89 million
Optionable
Optionable
Beta
0.60

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:RCKT) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners